Updates from IKCS 2023 and Surrounding Meetings in Advanced RCC

Brian Rini, MD, and Hans Hammers, MD, explore key data updates in the management of advanced renal cell carcinoma (RCC) presented at the 2023 IKCS: North America Congress and other recent meetings.

EP. 1: The Evolution of Advanced Renal Cell Carcinoma

December 13th 2023

Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.

EP. 2: CLEAR Trial: Lenvatinib plus Pembrolizumab in Advanced RCC

December 13th 2023

Experts highlight key clinical updates from the CLEAR trial presented at the 2023 IKCS: North America congress, assessing lenvatinib plus pembrolizumab in patients with advanced RCC.

EP. 3: Tackling Toxicity Management in Combination Regimens for Advanced RCC

December 20th 2023

A comprehensive discussion on toxicity management and patient tolerability for combination regimens in the setting of advanced RCC.

EP. 4: Impact of Treatment Selection and Real-World Outcomes in Advanced RCC

December 20th 2023

Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.

EP. 5: Data Updates in Advanced RCC from 2023 IKCS: North America

December 27th 2023

Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.

EP. 6: Future Outlooks in the Treatment of Advanced RCC

December 27th 2023

Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.